Contents

Search


guanethidine (Ismelin, Santensin)

Tradename: Ismelin. Indication: treatment of moderate to severe hypertension Contraindications: 1) pheochromocytoma 2) concurrent administration of MAO inhibitor Caution: 1) use with caution in the elderly 2) frequent occurrence of orthostatic hypotension Dosage: 1) adults a) start 10 mg PO QD b) increase by 10 mg/day at intervals of 5-7 days c) usual 25-50 mg/day 2) children a) start: 0.2 mg/kg/day up to 10 mg b) increase by 0.2 mg/kg every 1-3 weeks c) maximum dose: 3 mg/kg/day Tabs: 10 & 25 mg. Adverse effects: 1) common (> 10%) - palpitations, chest pain, peripheral edema, fatigue, headache, faintness, drowsiness, confusion, increased bowel movements, pain from flatulence, constipation, anorexia, weight gain/loss, nocturia, polyuria, retrograde ejaculation, paresthesia, muscle ache (especially leg cramps), backache, arthralgia, visual disturbances, shortness of breath, cough 2) less common (1-10%) - orthostatic hypotension, psychologic disturbance, depression, sleep disorder, glossitis, nausea/vomiting xerostomia, hematuria 3) uncommon (< 1%) - syncope, angina 4) other - fluid retention - diarrhea Drug interactions: 1) tricyclic antidepressants (TCA), antihistamines, ephedrine interfere with the action of guanethidine 2) phenothiazines 3) anorexiants 4) haloperidol 5) maprotiline 6) methylphenidate 7) MAO inhibitors Mechanism of action: - replaces norepinephrine within secretory granules of adrenergic neurons

Interactions

drug interactions drug adverse effects of antihypertensive agents

General

adrenergic neuron inhibitor

Properties

MISC-INFO: elimination route LIVER KIDNEY pregnancy-category C safety in lactation -

Database Correlations

PUBCHEM correlations

References

  1. The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996, pg 790
  2. Mayo Internal Medicine Board Review, 1998-99, Prakash UBS (ed) Lippincott-Raven, Philadelphia, 1998, pg 474
  3. Kaiser Permanente Northern California Regional Drug Formulary, 1998

Component-of

guanethidine/hydrochlorothiazide; guanethidine/HCTZ (Esmil)